AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30138394 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined copeptin/cTN testing
Number of subjects: 713
Study 30138394 — intervention group
Group type: COMPARATOR
Intervention: Serial cTN testing
Number of subjects: 713
Study 30138550 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP2K1-positive melorheostosis patients
Number of subjects: 15
Study 30138550 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected bone from MAP2K1-positive patients
Number of subjects: 15
Study 30138550 — intervention group
Group type: COMPARATOR
Intervention: MAP2K1-negative patients
Number of subjects: 15
Study 30138687 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver biopsy and transient elastography
Number of subjects: 94
Study 30138687 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of metabolic syndrome
Number of subjects: 94
Study 30138687 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient elastography
Number of subjects: 94
Study 30138687 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated abnormal AAT in hepatocytes, portal inflammation, and hepatocellular degeneration
Number of subjects: 94
Study 30138736 — intervention group
Group type: EXPERIMENTAL
Intervention: NCGWS patients
Number of subjects: 78
Study 30138736 — intervention group
Group type: COMPARATOR
Intervention: Non-NCGWS controls
Number of subjects: 78
Study 30138764 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab plus pemetrexed-carboplatin (PC)
Number of subjects: 123
Study 30138764 — intervention group
Group type: COMPARATOR
Intervention: PC alone
Number of subjects: 123
Study 30138764 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab plus PC
Number of subjects: 123
Study 30138841 — intervention group
Group type: EXPERIMENTAL
Intervention: General reproductive health visits with both current and past elevated depressive symptoms
Number of subjects: 1215
Study 30138841 — intervention group
Group type: EXPERIMENTAL
Intervention: Abortion patients with current elevated depressive symptoms
Number of subjects: 1215
Study 30139013 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe obstructive sleep apnea
Number of subjects: 0
Study 30139013 — intervention group
Group type: COMPARATOR
Intervention: Control group (no obstructive sleep apnea)
Number of subjects: 0
Study 30139368 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioning strategies for mesenchymal stem cells (MSCs)
Number of subjects: 0
Study 30139368 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 30139372 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine (CFZ) administered orally for 5 days
Number of subjects: 66
Study 30139372 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally for 5 days
Number of subjects: 66
Study 30139707 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive smoking-cessation intervention
Number of subjects: 5123
Study 30139707 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5123
Study 30139779 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCR2 antagonist danirixin
Number of subjects: 0
Study 30139779 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30139840 — intervention group
Group type: EXPERIMENTAL
Intervention: Linsitinib 450 mg daily on days 1-3 every 7 days and irinotecan 125 mg/m²
Number of subjects: 17
Study 30139840 — intervention group
Group type: EXPERIMENTAL
Intervention: Linsitinib 400 mg and irinotecan 100 mg/m²
Number of subjects: 17
Study 30139897 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication intake
Number of subjects: 50
Study 30139897 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-being
Number of subjects: 50
Study 30139897 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 50
Study 30139897 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 50
Study 30139897 — intervention group
Group type: COMPARATOR
Intervention: Symptoms (dizziness, headache, restlessness, fatigue, palpitations)
Number of subjects: 50
Study 30139899 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV) during general anaesthesia for robotic-assisted surgery (RAS)
Number of subjects: 0
Study 30139903 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-7 (720 µg/day) supplemented by vitamin D (25 µg/day)
Number of subjects: 400
Study 30139903 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (no active treatment)
Number of subjects: 400
Study 30140207 — intervention group
Group type: EXPERIMENTAL
Intervention: Excitatory Repetitive Transcranial Magnetic Stimulation (eTMS)
Number of subjects: 0
Study 30140582 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 592
Study 30140912 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 0
Study 30140912 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30141830 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting competitive swimming
Number of subjects: 0
Study 30142084 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week supervised exercise therapy alone
Number of subjects: 140
Study 30142084 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic partial meniscectomy alone
Number of subjects: 140
Study 30142422 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs) - specifically docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), and fish oil (FO)
Number of subjects: 5
Study 30142422 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 5
Study 30142422 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fish oil (FO) and cytarabine (AraC)
Number of subjects: 5
Study 30142751 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (LUTS)
Number of subjects: 4136
Study 30142751 — intervention group
Group type: EXPERIMENTAL
Intervention: Overactive bladder (OAB)
Number of subjects: 4136
Study 30142751 — intervention group
Group type: EXPERIMENTAL
Intervention: LUTS presence
Number of subjects: 4136
Study 30142751 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare visits for urinary symptoms
Number of subjects: 4136
Study 30143019 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Number of subjects: 128
Study 30143031 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 42
Study 30143412 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence in individuals with CD
Number of subjects: 0
Study 30143412 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 0
Study 30143412 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary habits of individuals with CD
Number of subjects: 0
Study 30143412 — intervention group
Group type: COMPARATOR
Intervention: Dietary habits of healthy participants
Number of subjects: 0
Study 30143448 — intervention group
Group type: EXPERIMENTAL
Intervention: Kardia Mobile Cardiac Monitor (KMCM) automated algorithm
Number of subjects: 52
Study 30143448 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-interpreted KMCM recordings
Number of subjects: 52
Study 30143448 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician interpretation of KMCM recordings
Number of subjects: 52
Study 30143448 — intervention group
Group type: COMPARATOR
Intervention: Unclassified recordings by KMCM algorithm
Number of subjects: 52
Study 30143454 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinkers
Number of subjects: 42
Study 30143455 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV care linkage
Number of subjects: 831
Study 30143455 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiation
Number of subjects: 831
Study 30143455 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention in care after starting ART
Number of subjects: 831
Study 30143455 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load testing
Number of subjects: 831
Study 30143455 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral suppression
Number of subjects: 831
Study 30143455 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss to follow-up after starting treatment
Number of subjects: 831
Study 30143455 — intervention group
Group type: COMPARATOR
Intervention: Treatment initiation likelihood based on site type
Number of subjects: 831
Study 30143455 — intervention group
Group type: COMPARATOR
Intervention: Viral suppression likelihood based on education level
Number of subjects: 831
Study 30143474 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Heating System 2.2 (THS 2.2)
Number of subjects: 984
Study 30143474 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking of combustible cigarettes
Number of subjects: 984
Study 30143477 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Coach app combined with Fitbit activity tracker (n=60)
Number of subjects: 130
Study 30143477 — intervention group
Group type: COMPARATOR
Intervention: Print-based generic physical activity information (Control group)
Number of subjects: 130
Study 30144299 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving minimal disease activity (MDA) at 12 months
Number of subjects: 101
Study 30144299 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained minimal disease activity (sMDA)
Number of subjects: 101
Study 30144299 — intervention group
Group type: COMPARATOR
Intervention: MDA group
Number of subjects: 101
Study 30144299 — intervention group
Group type: COMPARATOR
Intervention: Non-MDA group
Number of subjects: 101
Study 30144299 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA maintenance
Number of subjects: 101
Study 30144422 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus and hydroxychloroquine
Number of subjects: 222
Study 30144803 — intervention group
Group type: EXPERIMENTAL
Intervention: non-HDL-C
Number of subjects: 1599
Study 30144803 — intervention group
Group type: EXPERIMENTAL
Intervention: TC/HDL
Number of subjects: 1599
Study 30144803 — intervention group
Group type: EXPERIMENTAL
Intervention: non-HDL-C, TC/HDL, TG/HDL, LDL/HDL
Number of subjects: 1599
Study 30144803 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual lipid parameters (TC, TG, LDL-C, HDL-C)
Number of subjects: 1599
Study 30144818 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted biopsy (VAB) guided by ultrasound or mammography
Number of subjects: 600
Study 30144981 — intervention group
Group type: EXPERIMENTAL
Intervention: FIRM ablation with PVAI
Number of subjects: 0
Study 30144981 — intervention group
Group type: COMPARATOR
Intervention: PVAI plus posterior wall isolation (PWI) and non-PV trigger ablation
Number of subjects: 0
Study 30145030 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 30145316 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal impedance (MI) measurements in EoE patients
Number of subjects: 33
Study 30145316 — intervention group
Group type: COMPARATOR
Intervention: Mucosal impedance (MI) measurements in control subjects
Number of subjects: 33
Study 30145316 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of eosinophils per high-power field (eos/HPF) with minimum MI
Number of subjects: 33
Study 30145316 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of eosinophils per high-power field (eos/HPF) with average MI
Number of subjects: 33
Study 30145316 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of endoscopic reference score with minimum MI
Number of subjects: 33
Study 30145316 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of endoscopic reference score with average MI
Number of subjects: 33
Study 30145316 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal MI segments in inactive EoE patients
Number of subjects: 33
Study 30145340 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory systolic BP
Number of subjects: 199
Study 30145340 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic systolic BP
Number of subjects: 199
Study 30145340 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine-to-sit time (mobility measure)
Number of subjects: 199
Study 30145340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive measures (Trails Making Test Part A and the Stroop Word Test)
Number of subjects: 199
Study 30145340 — intervention group
Group type: COMPARATOR
Intervention: Home systolic BP
Number of subjects: 199
Study 30146701 — intervention group
Group type: EXPERIMENTAL
Intervention: ZX008 (fenfluramine HCl) at an initial dose of 0.2 mg/kg/d, with escalations up to 0.8 mg/kg/d or 30 mg/d every 4 weeks in nonresponders.
Number of subjects: 13
Study 30146701 — intervention group
Group type: EXPERIMENTAL
Intervention: ZX008 (fenfluramine HCl) continued in long-term extension study after 20 weeks.
Number of subjects: 13
Study 30146701 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to ZX008 treatment.
Number of subjects: 13
Study 30148443 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad informed consent (IC)
Number of subjects: 146
Study 30148996 — intervention group
Group type: EXPERIMENTAL
Intervention: SULCS
Number of subjects: 61
Study 30148996 — intervention group
Group type: EXPERIMENTAL
Intervention: AMAT
Number of subjects: 61
Study 30148996 — intervention group
Group type: EXPERIMENTAL
Intervention: BBT
Number of subjects: 61
Study 30148996 — intervention group
Group type: EXPERIMENTAL
Intervention: FMA
Number of subjects: 61
Study 30149145 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (canagliflozin)
Number of subjects: 3667
Study 30149145 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (dapagliflozin)
Number of subjects: 3667
Study 30149145 — intervention group
Group type: EXPERIMENTAL
Intervention: Incretin agents (liraglutide)
Number of subjects: 3667
Study 30149145 — intervention group
Group type: EXPERIMENTAL
Intervention: Incretin agents (sitagliptin)
Number of subjects: 3667
Study 30149145 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further treatment)
Number of subjects: 3667
Study 30149823 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intakes of vegetables, fruit, and milk
Number of subjects: 2010
Study 30149823 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in food intake patterns
Number of subjects: 2010
Study 30149823 — intervention group
Group type: EXPERIMENTAL
Intervention: Contribution of cooked staple porridges and bread made from fortified maize and bread flour
Number of subjects: 2010
Study 30150316 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA-Seq technology using 25 ng of cfDNA
Number of subjects: 58
Study 30150316 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA-Seq technology
Number of subjects: 58
Study 30151192 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard operating procedures for managing patients with NTM respiratory infections
Number of subjects: 0
Study 30151972 — intervention group
Group type: EXPERIMENTAL
Intervention: Marzeptacog alfa (activated) at intravenous doses up to 30 μg kg
Number of subjects: 0
Study 30152164 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid cognitive-behavioral therapy intervention
Number of subjects: 21
Study 30152888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid vasopressin (AVP) concentration in children with autism
Number of subjects: 0
Study 30152888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid vasopressin (AVP) concentration
Number of subjects: 0
Study 30152888 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30153037 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen time
Number of subjects: 817
Study 30153037 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe obesity
Number of subjects: 817
Study 30153037 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 817
Study 30153046 — intervention group
Group type: COMPARATOR
Intervention: Mothers without asthma and without preeclampsia
Number of subjects: 806
Study 30153046 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers without asthma with preeclampsia
Number of subjects: 806
Study 30153046 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with asthma without preeclampsia
Number of subjects: 806
Study 30153046 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with asthma with preeclampsia
Number of subjects: 806
Study 30153232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam (single intravenous dose, age-based)
Number of subjects: 37
Study 30153232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam (single intravenous dose)
Number of subjects: 37
Study 30153529 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone deficiency (GHD) patients after aerobic exercise
Number of subjects: 14
Study 30153529 — intervention group
Group type: COMPARATOR
Intervention: Sedentary male control subjects (CS) after aerobic exercise
Number of subjects: 14
Study 30153638 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent suicide attempts (SA)
Number of subjects: 433
Study 30153638 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric hospitalization
Number of subjects: 433
Study 30153638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine dependence
Number of subjects: 433
Study 30153638 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedative use disorders
Number of subjects: 433
Study 30153790 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose behavioral treatment (DTI plus relaxation training)
Number of subjects: 20
Study 30153790 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose behavioral treatment (DTI plus relaxation training)
Number of subjects: 20
Study 30153871 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed state
Number of subjects: 3918
Study 30153871 — intervention group
Group type: EXPERIMENTAL
Intervention: Euthymic state
Number of subjects: 3918
Study 30153871 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed state
Number of subjects: 3918
Study 30153985 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient management
Number of subjects: 1571
Study 30153985 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1571
Study 30154022 — intervention group
Group type: EXPERIMENTAL
Intervention: WHOQOL-BREF questionnaire
Number of subjects: 202
Study 30154071 — intervention group
Group type: EXPERIMENTAL
Intervention: E-PrEP (social media-based, peer-led intervention)
Number of subjects: 152
Study 30154071 — intervention group
Group type: COMPARATOR
Intervention: E-Health (attention-matched general health control condition)
Number of subjects: 152
Study 30154071 — intervention group
Group type: EXPERIMENTAL
Intervention: E-PrEP
Number of subjects: 152
Study 30154193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral SD-101 in combination with pembrolizumab
Number of subjects: 22
Study 30154228 — intervention group
Group type: EXPERIMENTAL
Intervention: Hsp90 inhibitor luminespib (formerly AUY922)
Number of subjects: 0
Study 30154228 — intervention group
Group type: COMPARATOR
Intervention: EGFR inhibitors (first-, second-, and third-generation)
Number of subjects: 0
Study 30154229 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual MRI screening
Number of subjects: 295
Study 30154229 — intervention group
Group type: COMPARATOR
Intervention: Annual MG screening plus biannual MRI screening
Number of subjects: 295
Study 30154857 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy hysterectomy (MLH)
Number of subjects: 52
Study 30154857 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic assisted vaginal hysterectomy (LAVH)
Number of subjects: 52
Study 30154874 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric butterfly prototype nasal dilator strip
Number of subjects: 59
Study 30154874 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathe Right Nasal Strip (BRNS)
Number of subjects: 59
Study 30154874 — intervention group
Group type: COMPARATOR
Intervention: Asymmetric butterfly placebo strip
Number of subjects: 59
Study 30155268 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii™ Balance Board training
Number of subjects: 14
Study 30155268 — intervention group
Group type: COMPARATOR
Intervention: Conventional balance exercises
Number of subjects: 14
Study 30155282 — intervention group
Group type: EXPERIMENTAL
Intervention: HT (Thealoz Duo®) - sodium hyaluronate and trehalose
Number of subjects: 0
Study 30155282 — intervention group
Group type: EXPERIMENTAL
Intervention: HTC-gel (Thealoz Duo Gel) - hyaluronic acid, trehalose, and carbomer
Number of subjects: 0
Study 30155496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavitron ultrasonic surgical aspirator (CUSA)
Number of subjects: 11
Study 30156755 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous ex vivo expanded EPCs
Number of subjects: 18
Study 30156755 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline or autologous bone marrow stromal cells)
Number of subjects: 18
Study 30156755 — intervention group
Group type: EXPERIMENTAL
Intervention: EPC group
Number of subjects: 18
Study 30156755 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled group
Number of subjects: 18
Study 30156866 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion (CSII)
Number of subjects: 0
Study 30156866 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study 30156984 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib (400 mg twice per day) plus Gefitinib (250 mg once per day)
Number of subjects: 161
Study 30156984 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib (100-800 mg once per day or 200-600 mg twice per day) plus Gefitinib (250 mg once per day)
Number of subjects: 161
Study 30156984 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib plus Gefitinib
Number of subjects: 161
Study 30157009 — intervention group
Group type: EXPERIMENTAL
Intervention: In-house vocational training program
Number of subjects: 323
Study 30157009 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapists' pursuit of additional training or short-term apprenticeship
Number of subjects: 323
Study 30157009 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraining vocational counseling provided by community-based occupational therapists
Number of subjects: 323
Study 30157009 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of 6 months posttraining
Number of subjects: 323